Effects of Probiotics on Metabolic Syndrome: A Systematic Review of Randomized Clinical Trials
Metadata
Show full item recordAuthor
Tenorio-Jiménez, Carmen; Martínez Ramírez, María José; Gil Hernández, Ángel; Gómez Llorente, CarolinaEditorial
MDPI
Materia
Metabolic syndrome Gastrointestinal microbiome Probiotics Obesity
Date
2020-01-01Referencia bibliográfica
Tenorio-Jiménez, C., Martínez-Ramírez, M. J., Gil, Á., & Gómez-Llorente, C. (2020). Effects of Probiotics on Metabolic Syndrome: A Systematic Review of Randomized Clinical Trials. Nutrients, 12(1), 124.
Abstract
The aim of this systematic review is to evaluate whether the use of probiotics has any
effect on the components of metabolic syndrome (MetS) before patients develop type 2 diabetes.
A qualitative systematic review, following the Cochrane methodology, and a comprehensive literature
search of randomized controlled trials (RCTs) were conducted in PubMed and Scopus from inception
until 4 July 2019. According to our inclusion criteria, nine clinical studies were finally analyzed,
corresponding to six RCTs. Probiotics intake in patients with MetS resulted in improvements in
body mass index, blood pressure, glucose metabolism, and lipid profile in some studies. Regarding
inflammatory biomarkers, probiotics also positively affected the soluble vascular cell adhesion
molecule 1 (sVCAM-1), interleukine-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), vascular endothelial
growth factor (VEGF), and thrombomodulin. Despite the diversity of the published studies, the
intake of probiotics for patients with MetS may offer a discrete improvement in some of the clinical
characteristics of the MetS and a decrease in inflammatory biomarkers. Nevertheless, these beneficial
effects seem to be marginal compared to drug therapy and a healthy lifestyle and clinically non-relevant.